Sun Pharmaceutical Industries (SUNPHARMA) announced that the FDA has accepted for review the supplemental Biologics License Application for ILUMYA for the treatment of adults with active psoriatic arthritis. The FDA regulatory action date is expected by October 29, 2026. The sBLA is based on the results from the INSPIRE-1 and INSPIRE-2 Phase 3 clinical studies.
The company noted that if approved, this would mark a new indication for ILUMYA following its US FDA approval in 2018 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
At last close, Sun Pharma was trading at INR 1,776.00, down 1.42%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.